SCHEMBL4155959

SCHEMBL4155959

CS(=O)(=O)NCCCCn1c(CCO)nc2c(N)nc3cccnc3c21

nearest known ligand 0.61

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 17/20 0.61
TLR8 Q9NR97 5/20 0.42
HRH1 P35367 2/20 0.37
KCNH2 Q12809 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4151486 0.93 TLR7 (0.52) TLR7TLR8
SCHEMBL13652673 0.93 TLR7 (0.63) TLR7TLR8HRH1KCNH2
SCHEMBL2743937 0.87 TLR7 (0.80) TLR7TLR8
SCHEMBL4152641 0.85 TLR7 (0.53) TLR7TLR8
SCHEMBL13431440 0.85 TLR7 (0.55) TLR7TLR8
SCHEMBL4155819 0.82 TLR7 (0.50) TLR7
SCHEMBL4147486 0.80 TLR7 (0.52) TLR7TLR8
SCHEMBL2744306 0.79 TLR7 (0.83) TLR7TLR8
SCHEMBL6759213 0.79 TLR7 (0.56) TLR7TLR8
SCHEMBL3355143 0.79 TLR7 (0.54) TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-8343993-B2 Hydroxyalkyl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-01-01 US disclosed
US-8343993-B2 Hydroxyalkyl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-01-01 US disclosed
US-8343993-B2 Hydroxyalkyl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-01-01 US disclosed
US-20090253695-A1 Hydroxyalkyl Substituted Imidazonaphthyridines COLEY PHARMACEUTICAL GROUP, INC, (US) 2009-10-08 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed
EP-1851220-A2 HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES 3M Innovative Properties Company (US) 2007-11-07 EP disclosed
WO-2006091568-A2 HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon IFNG, IFNAR1, EIF2AK2 TLR7 194/4885TLR8 494/4885HRH1 882/4885
US-20090253695-A1 Hydroxyalkyl Substituted Imidazonaphthyridines IFNG, IFNAR1, IRF3 TLR7 68/4885TLR8 187/4885HRH1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.